Special Investigation For Long Term Use Of Tolterodine (Regulatory Post Marketing Commitment Plan).


Last updated date


Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center


By email


[email protected]

Call Now

Eligibility Criteria
The disease, disorder, syndrome, illness, or injury that is being studied.
Overactive Urinary Bladder
Females and Males
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0 +
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients need to be administered Detrusitol® Capsule in order to be enrolled in the surveillance.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients not administered Detrusitol® Capsule.


Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center


[email protected]

pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.


Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Overactive Urinary BladderA Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder.
  1. Wien,
  2. Antwerpen,
  3. Edegem,
  4. Gent,
  5. Kortrijk,
  6. Aarhus N,
  7. Glostrup,
  8. Helsinki,
  9. Kouvola,
  10. OYS,
  11. Tampere,
  12. Turku,
  13. Berlin,
  14. Berlin,
  15. Frankfurt,
  16. Hannover,
  17. Leipzig,
  18. Muenchen,
  19. Haifa,
  20. Haifa,
  21. Jerusalem,
  22. Foggia,
  23. Terracina, LT,
  24. Hamar,
  25. Oslo,
  26. Tonsberg,
  27. Trondheim,
  28. Coimbra,
  29. Lisboa,
  30. Porto,
  31. Porto,
  32. Porto,
  33. Bratislava,
  34. Bratislava,
  35. Galanta,
  36. Kosice - Saca,
  37. Kosice,
  38. Martorell, Barcelona
  39. Sabadell, Barcelona
  40. Getafe, Madrid
  41. Manacor, Palma de Mallorca
  42. Valencia,
  43. Eslov,
  44. Goteborg,
  45. Malmo,
  46. Malmo,
  47. Norrkoping,
  48. Stockholm,
  49. Frauenfeld,
  50. Ankara,
  51. Istanbul,
  52. Izmir,
  53. Samsun,
  54. Bexhill on Sea, East Sussex
  55. Leytonstone, London
  56. Harrow, Middlesex
  57. High Heaton, Newcastle upon Tyne
  58. Birmingham,
  59. London,
  60. London,
65 Years+
Overactive Urinary BladderA Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder.
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Birmingham, Alabama
  4. Huntsville, Alabama
  5. Montgomery, Alabama
  6. Phoenix, Arizona
  7. Sun Lakes, Arizona
  8. Bentonville, Arkansas
  9. Jonesboro, Arkansas
  10. Little Rock, Arkansas
  11. Buena Park, California
  12. Foothill Ranch, California
  13. Fresno, California
  14. West Covina, California
  15. Colorado Springs, Colorado
  16. Lakewood, Colorado
  17. Chipley, Florida
  18. Davie, Florida
  19. Hallandale, Florida
  20. Miami Beach, Florida
  21. Miami, Florida
  22. Murdock, Florida
  23. Ocala, Florida
  24. Pembroke Pines, Florida
  25. St. Cloud, Florida
  26. Tampa, Florida
  27. Atlanta, Georgia
  28. Barnesville, Georgia
  29. Blue Ridge, Georgia
  30. Decatur, Georgia
  31. Chicago, Illinois
  32. Naperville, Illinois
  33. Orland Park, Illinois
  34. Newton, Kansas
  35. Shawnee, Kansas
  36. Wichita, Kansas
  37. Wichita, Kansas
  38. Marrero, Louisiana
  39. Laurel, Maryland
  40. Oxon Hill, Maryland
  41. Jackson, Michigan
  42. Portage, Michigan
  43. St. Louis, Missouri
  44. Las Vegas, Nevada
  45. Las Vegas, Nevada
  46. Blackwood, New Jersey
  47. Mt. Laurel, New Jersey
  48. Binghamton, New York
  49. Endicott, New York
  50. Endwell, New York
  51. Kingston, New York
  52. Beaufort, North Carolina
  53. Charlotte, North Carolina
  54. Charlotte, North Carolina
  55. Durham, North Carolina
  56. Morehead City, North Carolina
  57. Winston-Salem, North Carolina
  58. Columbus, Ohio
  59. Kettering, Ohio
  60. Central Point, Oregon
  61. Medford, Oregon
  62. Bala Cynwyd, Pennsylvania
  63. Bensalem, Pennsylvania
  64. Connellsville, Pennsylvania
  65. Philadelphia, Pennsylvania
  66. Philadelphia, Pennsylvania
  67. Philadelphia, Pennsylvania
  68. Sellersville, Pennsylvania
  69. Stoneboro, Pennsylvania
  70. Warwick, Rhode Island
  71. Greer, South Carolina
  72. Simpsonville, South Carolina
  73. Cordova, Tennessee
  74. Huntingdon, Tennessee
  75. Lexington, Tennessee
  76. Savannah, Tennessee
  77. Selmer, Tennessee
  78. Waynesboro, Tennessee
  79. Austin, Texas
  80. Bryan, Texas
  81. Colleyville, Texas
  82. Friendswood, Texas
  83. Houston, Texas
  84. Plano, Texas
  85. Plano, Texas
  86. San Antonio, Texas
  87. Salt Lake City, Utah
  88. Salt Lake City, Utah
  89. West Jordan, Utah
  90. West Valley City, Utah
  91. Spokane, Washington
  92. Spokane, Washington
  93. Milwaukee, Wisconsin
  94. New Berlin, Wisconsin
  95. Oregon, Wisconsin
  96. Wauwatosa, Wisconsin
18 Years+
Overactive Urinary BladderPharmacokinetics and Relative Bioavailability Study
  1. Singapore,
21 Years+
Advanced Information
Descriptive Information
Brief Title Special Investigation For Long Term Use Of Tolterodine (Regulatory Post Marketing Commitment Plan).
Official Title Special Investigation For Long Term Use Of Detrusitol (Regulatory Post Marketing Commitment Plan).
Brief Summary The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.
Detailed Description All the patients whom an investigator prescribes the first Detrusitol® Capsule should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.
Study Type Observational
Study Design Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population The patients whom an investigator involving A6121187 prescribes the Tolterodine tartrate (Detrusitol® Capsule).
Condition Urinary Bladder, Overactive
Intervention Drug: Tolterodine tartrate
Detrusitol® Capsule 2mg and 4mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. " The usual adult dosage for oral administration is 4 mg of tolterodine tartrate once daily. Occasionally dose reduction might be needed due to individual tolerability."
Other Name: Detrusitol® Capsule.
Study Groups/Cohorts Tolterodine tartrate.
Patients taking Tolterodine tartrate.
Intervention: Drug: Tolterodine tartrate
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: June 5, 2012)
Original Estimated Enrollment
 (submitted: November 19, 2008)
Actual Study Completion Date March 2011
Actual Primary Completion Date March 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Patients need to be administered Detrusitol® Capsule in order to be enrolled in the surveillance.

Exclusion Criteria:

  • Patients not administered Detrusitol® Capsule.
Sexes Eligible for Study:All
Ages Child, Adult, Older Adult
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Not Provided
Removed Location Countries  
Administrative Information
NCT Number NCT00795509
Other Study ID Numbers A6121187
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date June 2012